Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in BMJ Retrieve available abstracts of 37 articles: HTML format

Single Articles

July 2026
1. NELSON F
   China has banned an unproven Alzheimer's operation and detained its inventor, but international clinical trials of dcLVA are still going ahead-why?
   BMJ. 2026;394:e100302.
   PubMed    
   
   
   
2. BARANIUK C
   Alzheimer's drug lecanemab: FDA approves easier initial use, with "huge implications" for UK.
   BMJ. 2026;394:e100318.
   PubMed    
   
   
   April 2026
3. BRAYNE C, Richard E
   Innovation in Alzheimer's disease needs more than pharmaceutical solutions.
   BMJ. 2026;393:s788.
   PubMed    
   
   
   
4. NOWELL J, Crook H, de Leon MJ, Edison P, et al
   Advances in the drug treatment of Alzheimer's disease: pathophysiology and mechanisms of action.
   BMJ. 2026;393:78881.
   PubMed     Abstract available
   
   
   
5. WISE J
   Alzheimer's drugs targeting amyloid do not produce clinically meaningful effects, concludes Cochrane review.
   BMJ. 2026;393:s719.
   PubMed    
   
   
   March 2026
6. IACOBUCCI G
   Alzheimer's drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal.
   BMJ. 2026;392:s551.
   PubMed    
   
   
   February 2026
7. 
   New treatments for Alzheimer's disease.
   BMJ. 2026;392:s273.
   PubMed    
   
   
   January 2026
8. VISSEL B
   Anti-amyloid antibodies for Alzheimer's disease are not truly disease modifying.
   BMJ. 2026;392:s28.
   PubMed    
   
   
   
9. NOLAN T
   Liraglutide for Alzheimer's disease . . . and other research.
   BMJ. 2026;392:r2633.
   PubMed    
   
   
   September 2025
10. NOGRADY B
    Lecanamab: Controversial Alzheimer's drug approved by Australian drugs regulator after two rejections.
    BMJ. 2025;390:r2056.
    PubMed    
    
    
    
11. BOWIE K
    Alzheimer's blood test could open door to new drugs on the NHS, researchers say.
    BMJ. 2025;390:r1916.
    PubMed    
    
    
    
12. DYER O
    Injectable Alzheimer's drug lecanemab approved in US for use at home.
    BMJ. 2025;390:r1888.
    PubMed    
    
    
    August 2025
13. VAN GOOL WA, Siebrand JAF, Brayne C, Larson EB, et al
    Evidence gap in blood biomarkers for Alzheimer's disease.
    BMJ. 2025;390:e084781.
    PubMed    
    
    
    June 2025
14. IACOBUCCI G
    Benefits of Alzheimer's drugs remain too small to justify costs, says NICE.
    BMJ. 2025;389:r1270.
    PubMed    
    
    
    
15. MAHASE E
    Alzheimer's disease: Rise in new drugs being trialled sparks hope among experts.
    BMJ. 2025;389:r1148.
    PubMed    
    
    
    May 2025
16. TANNE JH
    FDA approves blood test to diagnose Alzheimer's.
    BMJ. 2025;389:r1082.
    PubMed    
    
    
    April 2025
17. BAKCHINE S, Colosimo C, Emilsson E, Jonsdottir SE, et al
    Concerns about the approval of lecanemab for Alzheimer's disease.
    BMJ. 2025;389:r778.
    PubMed    
    
    
    
18. IACOBUCCI G
    Lecanemab: Experts criticise European Commission approval of Alzheimer's drug.
    BMJ. 2025;389:r796.
    PubMed    
    
    
    March 2025
19. MAHASE E
    Lecanemab and donanemab: NICE reconsiders controversial Alzheimer's drugs.
    BMJ. 2025;388:r463.
    PubMed    
    
    
    
20. WISE J
    Lecanemab: European drug agency upholds decision to recommend Alzheimer's drug.
    BMJ. 2025;388:r439.
    PubMed    
    
    
    December 2024
21. R PATEL V, Liu M, Worsham CM, Jena AB, et al
    Alzheimer's disease mortality among taxi and ambulance drivers: population based cross sectional study.
    BMJ. 2024;387:e082194.
    PubMed     Abstract available
    
    
    November 2024
22. MAHASE E
    Alzheimer's disease: What treatments could be rolled out in the next few years?
    BMJ. 2024;387:q2477.
    PubMed    
    
    
    October 2024
23. MAHASE E
    NICE rejects Alzheimer's drug donanemab owing to cost and "significant health risks".
    BMJ. 2024;387:q2342.
    PubMed    
    
    
    September 2024
24. LENZER J, Brownlee S
    Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug.
    BMJ. 2024;386:q2010.
    PubMed    
    
    
    August 2024
25. KMIETOWICZ Z, Mahase E
    Lecanemab: Benefits of Alzheimer's drug are "just too small" to justify cost, says NICE.
    BMJ. 2024;386:q1853.
    PubMed    
    
    
    July 2024
26. MAHASE E
    Lecanemab: European drug agency rejects Alzheimer's drug amid debate over efficacy and safety.
    BMJ. 2024;386:q1692.
    PubMed    
    
    
    
27. DYER O
    Scientist who worked on Cassava's Alzheimer drug simufilam charged with fraud.
    BMJ. 2024;386:q1568.
    PubMed    
    
    
    June 2024
28. DYER O
    Donanemab: FDA experts recommend approval of Alzheimer's drug.
    BMJ. 2024;385:q1327.
    PubMed    
    
    
    May 2024
29. NOLAN T
    A potential new treatment for Alzheimer's disease ... and other research.
    BMJ. 2024;385:q1125.
    PubMed    
    
    
    February 2024
30. IACOBUCCI G
    Sixty seconds on . . . Viagra and Alzheimer's disease.
    BMJ. 2024;384:q370.
    PubMed    
    
    
    
31. DYER O
    Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare.
    BMJ. 2024;384:q281.
    PubMed    
    
    
    October 2023
32. DALY TP
    Informing consent to antibodies in Alzheimer's disease.
    BMJ. 2023;383:p2350.
    PubMed    
    
    
    August 2023
33. HOWARD R, Kales HC
    New treatments for Alzheimer's disease.
    BMJ. 2023;382:1852.
    PubMed    
    
    
    July 2023
34. IACOBUCCI G
    Donanemab leads to modest slowing of Alzheimer's progression, study finds.
    BMJ. 2023;382:p1659.
    PubMed    
    
    
    
35. MAHASE E
    Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning.
    BMJ. 2023;382:p1580.
    PubMed    
    
    
    June 2023
36. POURHADI N, Morch LS, Holm EA, Torp-Pedersen C, et al
    Menopausal hormone therapy and dementia: nationwide, nested case-control study.
    BMJ. 2023;381:e072770.
    PubMed     Abstract available
    
    
    March 2023
37. TANNE JH
    Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.
    BMJ. 2023;380:p628.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum